(MedPage Today) — SAN ANTONIO — Preoperative radiotherapy (RT) plus PD-1 inhibitor pembrolizumab (Keytruda) significantly increased immune activation and tumor response in node-positive hormone receptor-positive (HR+)/HER2-negative breast cancer…
(MedPage Today) — SAN ANTONIO — Preoperative radiotherapy (RT) plus PD-1 inhibitor pembrolizumab (Keytruda) significantly increased immune activation and tumor response in node-positive hormone receptor-positive (HR+)/HER2-negative breast cancer…